Kevin Johnson
Clinical and Scientific Advisory Group
Clinical development
Capellabioscience
United Kingdom
Biography
Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.Kevin was CEO of PanGenetics, a Netherlands-based antibody development company and Index investment. He was part of the team at Cambridge Antibody Technology (CAT), becoming head of research in 1994. In 1997 he was appointed to the board as Research Director and Chief Technology Officer. He led development of CAT’s platform technologies and their application in the discovery of a number of human antibodies currently in clinical development.
Research Interest
Molecular biology
